Inogen logo
Inogen INGN
$ 6.43 0.16%
report update icon

Quarterly report 2026-Q1
added 05-08-2026

Inogen Balance Sheet 2025-2011 | INGN

Brief overview of Inogen's financial position

Balance sheet changes are traced across five available annual reports between 2021 and 2025.

The asset base decreased -39%, from $489.5 million to $298.6 million. Resources became smaller over the five periods.

Liabilities expanded faster than the asset base, -10.8% versus -39%. Debt-service capacity deserves attention.

Equity funds 64.4% of assets versus 75.6% initially. This creates a conservative balance sheet structure.

Negative net debt of -$86.3 million means cash holdings are larger than debt obligations.

The cash share moved from 48.1% to 34.7%. A higher figure generally provides more room in an adverse scenario.

The accumulated result is -$175.6 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.

Conclusion

Inogen's balance sheet profile is moderate. It should be considered alongside profitability, cash flow and liability maturities.

Annual Balance Sheet Inogen

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-86.3 M -94.4 M -104 M -164 M -209 M -202 M -191 M -197 M -143 M -92.9 M -65.8 M -56.2 M -2.87 M -6.18 M 5.72 M

Long Term Debt

14.3 M 16.6 M 18.3 M 19.8 M 23.3 M 8.08 M - - - - - 315 K 5.39 M 5.06 M 7.1 M

Long Term Debt Current

3.16 M 2.81 M 3.65 M 3.52 M 3.39 M 1.93 M 2.01 M - - - 315 K 299 K - - -

Total Non Current Liabilities

- - - - - - 52.5 M 18.9 M 14.1 M 9.12 M 5.28 M 3.2 M 6.43 M 5.22 M 7.43 M

Total Current Liabilities

63.5 M 76.7 M 72.5 M 65.3 M 61.5 M 56.7 M 50.2 M 46.6 M 33.9 M 22.8 M 22 M 18.7 M - - -

Total Liabilities

106 M 122 M 121 M 108 M 119 M 112 M 103 M 65.5 M 48 M 32 M 27.3 M 21.9 M 26.1 M 19 M 16.6 M

Deferred Revenue

- - - - - - 5.48 M 4.45 M 3.53 M 2.24 M 2.32 M 2.32 M 1.49 M 1.09 M 594 K

Retained Earnings

-176 M -153 M -117 M -14.5 M 69.3 M 75.6 M 81.4 M 60.5 M 8.64 M -12.4 M -45.1 M -56.7 M -62.6 M -81 M -75.8 M

Total Assets

299 M 296 M 326 M 405 M 490 M 462 M 447 M 376 M 275 M 214 M 161 M 140 M 82.4 M 47.6 M 24.1 M

Cash and Cash Equivalents

104 M 114 M 125 M 187 M 236 M 212 M 198 M 197 M 143 M 92.9 M 66.1 M 56.8 M 13.5 M 15.1 M -

Book Value

192 M 174 M 205 M 297 M 370 M 350 M 345 M 310 M 227 M 182 M 134 M 118 M 56.3 M 28.6 M 7.56 M

Total Shareholders Equity

192 M 174 M 205 M 297 M 370 M 350 M 345 M 310 M 227 M 182 M 134 M 118 M -62.4 M -80.8 M -

All numbers in USD currency

Quarterly Balance Sheet Inogen

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

13.4 M 15.1 M 16 M 16.3 M 16.6 M 17.4 M 18.1 M 18.6 M 18.3 M 18.9 M 18.3 M 19.2 M 19.8 M 20.7 M - 22.4 M 23.3 M 24.1 M 24.9 M 16.4 M 8.08 M 8.08 M 8.08 M 8.08 M 4.7 M 4.7 M 4.7 M 4.7 M - - - - - - - - - 80 K 159 K 238 K 315 K 80 K 159 K 237 K 315 K 315 K 315 K 315 K 5.39 M 5.39 M 5.39 M 5.39 M - - - - - - - -

Total Liabilities

103 M 110 M 113 M 110 M 122 M 121 M 121 M 124 M 121 M 113 M 99.6 M 104 M 108 M 119 M - 116 M 119 M 122 M 127 M 120 M 112 M 112 M 112 M 112 M 103 M 103 M 103 M 103 M 65.5 M 65.5 M 65.5 M 65.5 M 48 M 48 M 48 M 48 M 32 M 32 M 32 M 32 M 27.3 M 27.3 M 27.3 M 27.3 M 21.9 M 21.9 M 21.9 M 21.9 M 26.1 M 26.1 M 26.1 M 26.1 M - - - - - - - -

Deferred Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 3.15 M 3.53 M 3.65 M 3.58 M 2.76 M 2.24 M 2.24 M 2.24 M 2.24 M 2.32 M 2.32 M 2.32 M 2.32 M 2.32 M 2.32 M 2.32 M 2.32 M 1.49 M 1.49 M 1.49 M 1.49 M - - - - - - - -

Retained Earnings

-184 M -168 M -163 M -159 M -153 M -143 M -137 M -132 M -117 M -90.4 M -44.7 M -34.8 M -14.5 M 42.1 M - 55.1 M 69.3 M 92.1 M 80 M 74.9 M 75.6 M 75.6 M 75.6 M 75.6 M 81.4 M 81.4 M 81.4 M 81.4 M 60.5 M 60.5 M 60.5 M 60.5 M 8.64 M 8.64 M 8.64 M 8.64 M -12.4 M -12.4 M -12.4 M -12.4 M -45.1 M -45.1 M -45.1 M -45.1 M -56.7 M -56.7 M -56.7 M -56.7 M -62.6 M -62.6 M -62.6 M -62.6 M - - - - - - - -

Total Assets

286 M 307 M 312 M 308 M 296 M 306 M 309 M 316 M 326 M 344 M 374 M 386 M 405 M 470 M - 475 M 490 M 513 M 498 M 476 M 462 M 462 M 462 M 462 M 447 M 447 M 447 M 447 M 376 M 376 M 376 M 376 M 275 M 275 M 275 M 275 M 214 M 214 M 214 M 214 M 161 M 161 M 161 M 161 M 140 M 140 M 140 M 140 M 82.4 M 82.4 M 82.4 M 82.4 M - - - - - - - -

Cash and Cash Equivalents

93.1 M 106 M 104 M 119 M 114 M 106 M 97.9 M 107 M 125 M 125 M 168 M 164 M 187 M 210 M - 213 M 236 M 242 M 239 M 220 M 212 M 212 M 212 M 212 M 198 M 198 M 198 M 198 M 197 M 197 M 197 M 197 M 143 M 143 M 143 M 143 M 92.9 M 92.9 M 92.9 M 92.9 M 66.1 M 66.1 M 66.1 M 66.1 M 56.8 M 56.8 M 56.8 M 56.8 M 13.5 M 13.5 M 13.5 M 13.5 M 15.1 M 15.1 M - - 3.91 M - - -

Book Value

183 M 197 M 199 M 198 M 174 M 185 M 188 M 192 M 205 M 231 M 275 M 281 M 297 M 351 M - 358 M 370 M 391 M 371 M 356 M 350 M 350 M 350 M 350 M 345 M 345 M 345 M 345 M 310 M 310 M 310 M 310 M 227 M 227 M 227 M 227 M 182 M 182 M 182 M 182 M 134 M 134 M 134 M 134 M 118 M 118 M 118 M 118 M 56.3 M 56.3 M 56.3 M 56.3 M - - - - - - - -

Total Shareholders Equity

183 M 197 M 199 M 198 M 174 M 185 M 188 M 192 M 205 M 231 M 275 M 281 M 297 M 351 M 357 M 358 M 370 M 391 M 371 M 356 M 350 M 350 M 350 M 350 M 345 M 345 M 345 M 345 M 310 M 310 M 310 M 310 M 227 M 227 M 227 M 227 M 182 M 182 M 182 M 182 M 134 M 134 M 134 M 134 M 118 M 118 M 118 M 118 M -62.4 M -62.4 M -62.4 M -62.4 M -80.8 M - - - -75.6 M - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Inogen, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Medical devices

Issuer Price % 24h Market Cap Country
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Myomo Myomo
MYO
$ 0.93 -3.11 % $ 38.9 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
- - $ 162 M franceFrance
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Profound Medical Corp. Profound Medical Corp.
PROF
$ 7.24 -0.14 % $ 219 M canadaCanada
AxoGen AxoGen
AXGN
$ 41.37 0.53 % $ 1.91 B usaUSA
Quanterix Corporation Quanterix Corporation
QTRX
$ 3.38 -3.15 % $ 144 M usaUSA
AVITA Medical AVITA Medical
RCEL
$ 4.44 -3.69 % $ 124 M australiaAustralia
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 61.74 -1.86 % $ 9.37 B usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Smith & Nephew plc Smith & Nephew plc
SNN
$ 32.66 0.31 % $ 28.3 B britainBritain
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Tactile Systems Technology Tactile Systems Technology
TCMD
$ 27.4 -1.23 % $ 627 M usaUSA
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Tandem Diabetes Care Tandem Diabetes Care
TNDM
$ 18.59 4.67 % $ 1.26 B usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 14.14 -2.68 % $ 400 M usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.86 -1.95 % $ 14.6 M usaUSA
Avanos Medical Avanos Medical
AVNS
$ 24.99 - $ 1.16 B usaUSA
Viemed Healthcare Viemed Healthcare
VMD
$ 11.65 -2.27 % $ 453 M usaUSA
Varex Imaging Corporation Varex Imaging Corporation
VREX
$ 10.95 -1.62 % $ 453 M usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.35 -4.32 % $ 21.8 M usaUSA
LENSAR LENSAR
LNSR
$ 5.25 -1.87 % $ 62.8 M usaUSA
Beyond Air Beyond Air
XAIR
$ 5.51 0.92 % $ 45.7 B usaUSA
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
Xtant Medical Holdings Xtant Medical Holdings
XTNT
$ 0.43 0.14 % $ 60 M usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
Zimmer Biomet Holdings Zimmer Biomet Holdings
ZBH
$ 97.15 1.46 % $ 19.2 B usaUSA